Plasma-derived antithrombin is already approved for DIC/sepsis in Japan and some European countries, but I guess that’s a detail that wasn’t consistent with your message.
And I would refer you to the Kybersept study which showed that AT3 failed in its clinical trial and showed an additional risk of hemorrhage. Please stop now. I dont feel like getting into a dragged out debate about sepsis. Thanks, Dew.
Market Data 
Markets 
AI
